Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease

Ami V. Desai; Mark A. Applebaum; Theodore G. Karrison; Akosua Oppong; Cindy Yuan; Katherine R. Berg; Kyle MacQuarrie; Elizabeth Sokol; Anurekha G. Hall; Navin Pinto; Ian Wolfe; Rajen Mody; Suzanne Shusterman; Valeria Smith; Jennifer H. Foster; Michele Nassin; James L. LaBelle; Rochelle Bagatell; Susan L. Cohn

doi:10.1002/cncr.34263

Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease

Ami V. Desai^*, Mark A. Applebaum, Theodore G. Karrison, Akosua Oppong, Cindy Yuan, Katherine R. Berg, Kyle MacQuarrie, Elizabeth Sokol, Anurekha G. Hall, Navin Pinto, Ian Wolfe, Rajen Mody, Suzanne Shusterman, Valeria Smith, Jennifer H. Foster, Michele Nassin, James L. LaBelle, Rochelle Bagatell, Susan L. Cohn

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

BACKGROUND: High-risk neuroblastoma patients with end-induction residual disease commonly receive post-induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors conducted a multicenter, retrospective study to investigate the efficacy of this approach. METHODS: Patients diagnosed between 2008 and 2018 without progressive disease with a partial response or worse at end-induction were stratified according to the post-induction treatment: 1) no additional therapy before ASCT (cohort 1), 2) post-induction “bridge” therapy before ASCT (cohort 2), and 3) post-induction therapy without ASCT (cohort 3). χ² tests were used to compare patient characteristics. Three-year event-free survival (EFS) and overall survival (OS) were estimated by the Kaplan-Meier method and survival curves were compared by log-rank test. RESULTS: The study cohort consisted of 201 patients: cohort 1 (n = 123), cohort 2 (n = 51), and cohort 3 (n = 27). Although the end-induction response was better for cohort 1 than cohorts 2 and 3, the outcomes for cohorts 1 and 2 were not significantly different (P =.77 for EFS and P =.85 for OS). Inferior outcomes were observed for cohort 3 (P <.001 for EFS and P =.06 for OS). Among patients with end-induction stable metastatic disease, 3-year EFS was significantly improved for cohort 2 versus cohort 1 (P =.04). Cohort 3 patients with a complete response at metastatic sites after post-induction therapy had significantly better 3-year EFS than those with residual metastatic disease (P =.01). CONCLUSIONS: Prospective studies to confirm the benefits of bridge treatment and the prognostic significance of metastatic response observed in this study are warranted.

Original language	English (US)
Pages (from-to)	2967-2977
Number of pages	11
Journal	cancer
Volume	128
Issue number	15
DOIs	https://doi.org/10.1002/cncr.34263
State	Published - Aug 1 2022

Funding

This work was supported in part by the Matthew Bittker Foundation (to Susan L. Cohn), a gift from the MacRitchie Family (to Susan L. Cohn), and the National Institutes of Health/National Cancer Institute (K08CA226237; to Mark A. Applebaum; P30CA014599; to Theodore G. Karrison).

Keywords

autologous transplantation
neuroblastoma
prognosis
survival
treatment response

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cncr.34263

Cite this

Desai, A. V., Applebaum, M. A., Karrison, T. G., Oppong, A., Yuan, C., Berg, K. R., MacQuarrie, K., Sokol, E., Hall, A. G., Pinto, N., Wolfe, I., Mody, R., Shusterman, S., Smith, V., Foster, J. H., Nassin, M., LaBelle, J. L., Bagatell, R., & Cohn, S. L. (2022). Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. cancer, 128(15), 2967-2977. https://doi.org/10.1002/cncr.34263

@article{fbf0a67bdca046678b30c80e22dd64cb,

title = "Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease",

abstract = "BACKGROUND: High-risk neuroblastoma patients with end-induction residual disease commonly receive post-induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors conducted a multicenter, retrospective study to investigate the efficacy of this approach. METHODS: Patients diagnosed between 2008 and 2018 without progressive disease with a partial response or worse at end-induction were stratified according to the post-induction treatment: 1) no additional therapy before ASCT (cohort 1), 2) post-induction “bridge” therapy before ASCT (cohort 2), and 3) post-induction therapy without ASCT (cohort 3). χ2 tests were used to compare patient characteristics. Three-year event-free survival (EFS) and overall survival (OS) were estimated by the Kaplan-Meier method and survival curves were compared by log-rank test. RESULTS: The study cohort consisted of 201 patients: cohort 1 (n = 123), cohort 2 (n = 51), and cohort 3 (n = 27). Although the end-induction response was better for cohort 1 than cohorts 2 and 3, the outcomes for cohorts 1 and 2 were not significantly different (P =.77 for EFS and P =.85 for OS). Inferior outcomes were observed for cohort 3 (P <.001 for EFS and P =.06 for OS). Among patients with end-induction stable metastatic disease, 3-year EFS was significantly improved for cohort 2 versus cohort 1 (P =.04). Cohort 3 patients with a complete response at metastatic sites after post-induction therapy had significantly better 3-year EFS than those with residual metastatic disease (P =.01). CONCLUSIONS: Prospective studies to confirm the benefits of bridge treatment and the prognostic significance of metastatic response observed in this study are warranted.",

keywords = "autologous transplantation, neuroblastoma, prognosis, survival, treatment response",

author = "Desai, {Ami V.} and Applebaum, {Mark A.} and Karrison, {Theodore G.} and Akosua Oppong and Cindy Yuan and Berg, {Katherine R.} and Kyle MacQuarrie and Elizabeth Sokol and Hall, {Anurekha G.} and Navin Pinto and Ian Wolfe and Rajen Mody and Suzanne Shusterman and Valeria Smith and Foster, {Jennifer H.} and Michele Nassin and LaBelle, {James L.} and Rochelle Bagatell and Cohn, {Susan L.}",

note = "Funding Information: This work was supported in part by the Matthew Bittker Foundation (to Susan L. Cohn), a gift from the MacRitchie Family (to Susan L. Cohn), and the National Institutes of Health/National Cancer Institute (K08CA226237; to Mark A. Applebaum; P30CA014599; to Theodore G. Karrison). Publisher Copyright: {\textcopyright} 2022 American Cancer Society.",

year = "2022",

month = aug,

day = "1",

doi = "10.1002/cncr.34263",

language = "English (US)",

volume = "128",

pages = "2967--2977",

journal = "cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "15",

}

Desai, AV, Applebaum, MA, Karrison, TG, Oppong, A, Yuan, C, Berg, KR, MacQuarrie, K, Sokol, E, Hall, AG, Pinto, N, Wolfe, I, Mody, R, Shusterman, S, Smith, V, Foster, JH, Nassin, M, LaBelle, JL, Bagatell, R & Cohn, SL 2022, 'Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease', cancer, vol. 128, no. 15, pp. 2967-2977. https://doi.org/10.1002/cncr.34263

TY - JOUR

T1 - Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease

AU - Desai, Ami V.

AU - Applebaum, Mark A.

AU - Karrison, Theodore G.

AU - Oppong, Akosua

AU - Yuan, Cindy

AU - Berg, Katherine R.

AU - MacQuarrie, Kyle

AU - Sokol, Elizabeth

AU - Hall, Anurekha G.

AU - Pinto, Navin

AU - Wolfe, Ian

AU - Mody, Rajen

AU - Shusterman, Suzanne

AU - Smith, Valeria

AU - Foster, Jennifer H.

AU - Nassin, Michele

AU - LaBelle, James L.

AU - Bagatell, Rochelle

AU - Cohn, Susan L.

N1 - Funding Information: This work was supported in part by the Matthew Bittker Foundation (to Susan L. Cohn), a gift from the MacRitchie Family (to Susan L. Cohn), and the National Institutes of Health/National Cancer Institute (K08CA226237; to Mark A. Applebaum; P30CA014599; to Theodore G. Karrison). Publisher Copyright: © 2022 American Cancer Society.

PY - 2022/8/1

Y1 - 2022/8/1

N2 - BACKGROUND: High-risk neuroblastoma patients with end-induction residual disease commonly receive post-induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors conducted a multicenter, retrospective study to investigate the efficacy of this approach. METHODS: Patients diagnosed between 2008 and 2018 without progressive disease with a partial response or worse at end-induction were stratified according to the post-induction treatment: 1) no additional therapy before ASCT (cohort 1), 2) post-induction “bridge” therapy before ASCT (cohort 2), and 3) post-induction therapy without ASCT (cohort 3). χ2 tests were used to compare patient characteristics. Three-year event-free survival (EFS) and overall survival (OS) were estimated by the Kaplan-Meier method and survival curves were compared by log-rank test. RESULTS: The study cohort consisted of 201 patients: cohort 1 (n = 123), cohort 2 (n = 51), and cohort 3 (n = 27). Although the end-induction response was better for cohort 1 than cohorts 2 and 3, the outcomes for cohorts 1 and 2 were not significantly different (P =.77 for EFS and P =.85 for OS). Inferior outcomes were observed for cohort 3 (P <.001 for EFS and P =.06 for OS). Among patients with end-induction stable metastatic disease, 3-year EFS was significantly improved for cohort 2 versus cohort 1 (P =.04). Cohort 3 patients with a complete response at metastatic sites after post-induction therapy had significantly better 3-year EFS than those with residual metastatic disease (P =.01). CONCLUSIONS: Prospective studies to confirm the benefits of bridge treatment and the prognostic significance of metastatic response observed in this study are warranted.

AB - BACKGROUND: High-risk neuroblastoma patients with end-induction residual disease commonly receive post-induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors conducted a multicenter, retrospective study to investigate the efficacy of this approach. METHODS: Patients diagnosed between 2008 and 2018 without progressive disease with a partial response or worse at end-induction were stratified according to the post-induction treatment: 1) no additional therapy before ASCT (cohort 1), 2) post-induction “bridge” therapy before ASCT (cohort 2), and 3) post-induction therapy without ASCT (cohort 3). χ2 tests were used to compare patient characteristics. Three-year event-free survival (EFS) and overall survival (OS) were estimated by the Kaplan-Meier method and survival curves were compared by log-rank test. RESULTS: The study cohort consisted of 201 patients: cohort 1 (n = 123), cohort 2 (n = 51), and cohort 3 (n = 27). Although the end-induction response was better for cohort 1 than cohorts 2 and 3, the outcomes for cohorts 1 and 2 were not significantly different (P =.77 for EFS and P =.85 for OS). Inferior outcomes were observed for cohort 3 (P <.001 for EFS and P =.06 for OS). Among patients with end-induction stable metastatic disease, 3-year EFS was significantly improved for cohort 2 versus cohort 1 (P =.04). Cohort 3 patients with a complete response at metastatic sites after post-induction therapy had significantly better 3-year EFS than those with residual metastatic disease (P =.01). CONCLUSIONS: Prospective studies to confirm the benefits of bridge treatment and the prognostic significance of metastatic response observed in this study are warranted.

KW - autologous transplantation

KW - neuroblastoma

KW - prognosis

KW - survival

KW - treatment response

UR - http://www.scopus.com/inward/record.url?scp=85131635284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131635284&partnerID=8YFLogxK

U2 - 10.1002/cncr.34263

DO - 10.1002/cncr.34263

M3 - Article

C2 - 35665495

AN - SCOPUS:85131635284

SN - 0008-543X

VL - 128

SP - 2967

EP - 2977

JO - cancer

JF - cancer

IS - 15

ER -

Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this